Atara Biotherapeutics
ATRA
86 hedge funds and large institutions have $330M invested in Atara Biotherapeutics in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 18
13% more funds holding
Funds holding: 76 → 86 (+10)
3.22% more ownership
Funds ownership: 0% → 3.22% (+3.2%)
31% less capital invested
Capital invested by funds: $479M → $330M (-$149M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$11M |
| 2 |
AG
Artal Group
Luxembourg
|
+$4.66M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$4.07M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.92M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.7M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$6.4M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.99M |
| 4 |
BM
Bridger Management
New York
|
-$3.35M |
| 5 |
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
|
-$2.83M |
ATRA Hedge Fund Activity: Q4 2016 in Review
86 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2016, worth a combined $330M — down 31% from $479M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ATRA positions and 7 closed out — a net gain of 10 holders — while 36 added to existing stakes and 18 trimmed.
The largest buyer was Redmile Group, adding an estimated $11M. The largest seller was Fidelity Investments, cutting an estimated $12.7M.
- 86 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2016, up from 76 in Q3 2016.
- Funds reported $330M of Atara Biotherapeutics stock for Q4 2016, down 31% quarter-over-quarter.
- 17 funds opened new Atara Biotherapeutics positions in Q4 2016 and 7 closed out, a net change of +10 holders.
- The largest Atara Biotherapeutics buyer in Q4 2016 was Redmile Group, an estimated $11M added.
- The largest Atara Biotherapeutics seller in Q4 2016 was Fidelity Investments, an estimated $12.7M sold.
Based on aggregated 13F filings for Q4 2016.